IMP dehydrogenase and GTP as targets in human leukemia treatment.
Laboratory for Experimental Oncology, Indiana University School of Medicine, Indianapolis 46202-5200.
G
G
Weber
D000328:Adult; D000368:Aged; D000493:Allopurinol / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D016259:Genes, myc / Q000187:drug effects; D011905:Genes, ras / Q000187:drug effects; D006160:Guanosine Triphosphate / Q000378:metabolism*; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors*; D066298:In Vitro Techniques; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D012254:Ribavirin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism
D000970:Antineoplastic Agents; D012254:Ribavirin; D000493:Allopurinol; D006160:Guanosine Triphosphate; D007168:IMP Dehydrogenase; C033706:tiazofurin